NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) CFO Patrick Williams purchased 11,891 shares of NeuroPace stock in a transaction dated Tuesday, November 17th. The shares were bought at an average price of $8.34 per share, with a total value of $99,170.94. Following the completion of the transaction, the chief financial officer owned 79,399 shares in the company, valued at approximately $662,187.66. This trade represents a 17.61% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
NeuroPace Price Performance
Shares of NPCE traded up $0.23 on Tuesday, reaching $8.20. The stock had a trading volume of 684,069 shares, compared to its average volume of 219,143. The firm has a market capitalization of $281.42 million, a PE ratio of -14.64 and a beta of 1.98. The company has a quick ratio of 3.91, a current ratio of 4.94 and a debt-to-equity ratio of 4.97. The firm has a 50-day moving average of $13.07 and a 200 day moving average of $14.71. NeuroPace, Inc. has a twelve month low of $5.46 and a twelve month high of $19.60.
More NeuroPace News
Investors following NPCE have been watching these news items:
Wall Street Analyst Weigh In
A number of research analysts have recently weighed in on the company. KeyCorp dropped their price target on NeuroPace from $18.00 to $14.00 and set an "overweight" rating for the company in a research report on Friday. Weiss Ratings downgraded NeuroPace from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, October 2nd. Raymond James Financial set a $21.00 target price on NeuroPace in a research note on Tuesday, September 15th. Wolfe Research cut NeuroPace from a "strong-buy" rating to a "hold" rating in a report on Monday. Finally, Wall Street Zen cut NeuroPace from a "hold" rating to a "sell" rating in a report on Saturday. Five analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $13.11.
Read Our Latest Research Report on NeuroPace
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in NPCE. Soleus Capital Management L.P. lifted its holdings in NeuroPace by 10.5% in the 3rd quarter. Soleus Capital Management L.P. now owns 3,218,000 shares of the company's stock valued at $44,280,000 after purchasing an additional 306,878 shares in the last quarter. First Light Asset Management LLC boosted its stake in shares of NeuroPace by 16.3% during the 2nd quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company's stock worth $45,464,000 after purchasing an additional 401,201 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of NeuroPace during the second quarter worth about $39,369,000. Deutsche Bank AG purchased a new stake in shares of NeuroPace during the second quarter worth about $14,919,000. Finally, Algert Global LLC raised its position in shares of NeuroPace by 2.9% in the second quarter. Algert Global LLC now owns 184,774 shares of the company's stock valued at $2,936,000 after buying an additional 5,218 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company's stock.
About NeuroPace
(
Get Free Report)
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NeuroPace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.
While NeuroPace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.